Collaborative efforts driving progress in pediatric acute myeloid leukemia
CM Zwaan, EA Kolb, D Reinhardt… - Journal of clinical …, 2015 - ascopubs.org
Diagnosis, treatment, response monitoring, and outcome of pediatric acute myeloid
leukemia (AML) have made enormous progress during the past decades. Because AML is a …
leukemia (AML) have made enormous progress during the past decades. Because AML is a …
Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the …
Purpose To improve survival rates in children with acute myeloid leukemia (AML), we
evaluated gemtuzumab-ozogamicin (GO), a humanized immunoconjugate targeted against …
evaluated gemtuzumab-ozogamicin (GO), a humanized immunoconjugate targeted against …
Pediatric AML: from biology to clinical management
JDE De Rooij, CM Zwaan… - Journal of clinical …, 2015 - mdpi.com
Pediatric acute myeloid leukemia (AML) represents 15%–20% of all pediatric acute
leukemias. Survival rates have increased over the past few decades to~ 70%, due to …
leukemias. Survival rates have increased over the past few decades to~ 70%, due to …
[HTML][HTML] Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children's Oncology …
New therapeutic strategies are needed for pediatric acute myeloid leukemia (AML) to reduce
disease recurrence and treatment-related morbidity. The Children's Oncology Group Phase …
disease recurrence and treatment-related morbidity. The Children's Oncology Group Phase …
Pediatric acute myeloid leukemia—past, present, and future
D Reinhardt, E Antoniou, K Waack - Journal of clinical medicine, 2022 - mdpi.com
JCM | Free Full-Text | Pediatric Acute Myeloid Leukemia—Past, Present, and Future Next
Article in Journal Sexual Habits and Sexual Dysfunctions in a Sample of Patients with Psychotic …
Article in Journal Sexual Habits and Sexual Dysfunctions in a Sample of Patients with Psychotic …
Pediatric acute myeloid leukemia: updates on biology, risk stratification, and therapy
CW Elgarten, R Aplenc - Current Opinion in Pediatrics, 2020 - journals.lww.com
Further incorporation of genomic and molecular data in pediatric AML will allow for
additional refinements in risk stratification to enable the tailoring of treatment intensity. These …
additional refinements in risk stratification to enable the tailoring of treatment intensity. These …
Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric KMT2A-Rearranged AML: Results From the Phase III Children's Oncology …
PURPOSE We investigated the impact of the CD33-targeted agent gemtuzumab ozogamicin
(GO) on survival in pediatric patients with KMT2A-rearranged (KMT2A-r) acute myeloid …
(GO) on survival in pediatric patients with KMT2A-rearranged (KMT2A-r) acute myeloid …
Immunotherapy in hematologic malignancies: achievements, challenges and future prospects
L Tang, Z Huang, H Mei, Y Hu - Signal Transduction and Targeted …, 2023 - nature.com
The immune-cell origin of hematologic malignancies provides a unique avenue for the
understanding of both the mechanisms of immune responsiveness and immune escape …
understanding of both the mechanisms of immune responsiveness and immune escape …
Results of the AIEOP AML 2002/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia
We evaluated the outcome of 482 children with acute myeloid leukemia (AML) enrolled in
the Associazione Italiana di Ematologia e Oncologia Pediatrica AML 2002/01 trial …
the Associazione Italiana di Ematologia e Oncologia Pediatrica AML 2002/01 trial …